Anti-IL-6 agents have shown potential benefits in inflammatory disorders, but safety concerns, such as gastrointestinal perforations, have been raised based on previous studies with tocilizumab (a monoclonal antibody against IL-6R) in rheumatoid arthritis patients [72]. Here, IL6R is linked to rheumatoid arthritis.